Companies Dominating the Dry Eye Syndrome Landscape
- Lumenis Be Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Johnson & Johnson Services Inc.
- Alcon Vision LLC
- Allergan (AbbVie)
- Novartis AG
- Allostera Pharma Inc.
- I-Med Pharma Inc.
- Acadia Pharmaceutical Inc.
- Otsuka Pharmaceutical Co. Ltd.
- Sun Pharmaceutical Industries Ltd.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Dry Eye Syndrome Market in 2025 is evaluated at USD 7.41 billion.
The global market size crossed USD 6.98 billion in 2024 and is likely to register a CAGR of over 7.7%, exceeding USD 18.31 billion revenue by 2037.
North America is estimated to surpass largest share by 2037, driven by increasing cases of dry eye disease and higher adoption of eye care products.
The major players in the market include Lumenis Be Ltd., Johnson & Johnson Services Inc., Alcon Vision LLC, Allergan (AbbVie), Novartis AG, Allostera Pharma Inc., I-Med Pharma Inc., Acadia Pharmaceutical Inc., Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd.
